This Article  • Excerpt  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Arch Dermatol. 1996;132(3):250-252.

References
Article references have been provided for searching and linking. Additional reference information may be available in the article PDF.

* Single copies of this report will be available until February 10, 1996, from the CDC National AIDS Clearinghouse, PO Box 6005, Rockville, MD 20849-6003; telephone (800) 458-5231. Information on terminal illness in the source patient was missing for 19% of case-HCWs and 48% of control-HCWs; information on visible blood on device was missing for 3% of case-HCWs and 6% of control-HCWs. By recoding the missing values to zero and including missing value indicator variables for these factors in the model, these HCWs were retained in the analysis and their potential confounding influence could be assessed. No significant interactions were found among the risk factors in the model or between the risk factors and the missing value indicators. When all HCWs with missing values for any of the factors were excluded from the analysis, all of the factors remained significant, with similar adjusted odds ratios but larger confidence intervals. 1. Tokars JI, Marcus R, Culver DH, et al. Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood. Ann Intern Med 1993; 118:913-9. FREE FULL TEXT 2. Henderson DK. HIV-1 in the health care setting. In: Principles and practice of infectious diseases. 4th ed. Mandel GL, Bennett JE, Dolan R, eds. New York: Churchill Livingstone, 1995: 2632-56. 3. Ho DD, Mougil T, Alam M. Quantitation of HIV type 1 in the blood of infected persons. N Engl J Med 1989;321:1621-5. ABSTRACT 4. Richman DD, Bozzette S. The impact of syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994;169:968-74. PUBMED 5. Gerberding JL. Management of occupational exposures to blood-borne viruses. N Engl J Med 1995;332:444-51. FREE FULL TEXT 6. CDC. Recommendations of the U.S. Public Health Service task force on the use of zidovudine to reduce perinatal transmission of HIV. MMWR 1994;43(no. RR-11):1-20. PUBMED 7. Ho DD. Time to hit HIV, early and hard (Editorial). N Engl J Med 1995;333:450-1. FREE FULL TEXT 8. Puro V, Ippolito G, Guzzanti E, et al. Zidovudine prophylaxis after accidental exposure to HIV: the Italian experience. AIDS 1992;6:963-9. PUBMED 9. CDC. Public Health Service statement on management of occupational exposure to human immunodeficiency virus, including considerations regarding zidovudine postexposure use. MMWR 1990;39(no. RR-1).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?